| Thrombolysis in the management of acute myocardial infarction. Current status and future perspectives. | |
| | |
MedLine Citation:
|
PMID: 9973856 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The optimal thrombolytic regimen is front-loaded alteplase with vigorous heparinization: the reperfusion treatment that leads to the lowest 30 day mortality. The role of heparin alone or in combination with thrombolysis is still unclear. Hirudin does not provide benefit over heparin, as we have seen in the trials, and glycoprotein blockers are promising in PTCA. They can also be effective in unstable angina and possibly in acute myocardial infarction. |
| | |
Authors:
|
F Verheugt |
Related Documents
:
|
11530146 - Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfra... 18226876 - Do patients with acute myocardial infarction benefit from treatment with clopidogrel? 18473866 - Safety and efficacy of bivalirudin in acute coronary syndromes. 18349026 - Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after... 19850366 - The impact of infarct type on the reliability of early oral glucose tolerance testing i... 22767536 - Mitral valve involvement as a predominant feature of cardiac amyloidosis. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology Volume: 17 ISSN: 0870-2551 ISO Abbreviation: Rev Port Cardiol Publication Date: 1998 Dec |
Date Detail:
|
Created Date: 1999-03-05 Completed Date: 1999-03-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8710716 Medline TA: Rev Port Cardiol Country: PORTUGAL |
Other Details:
|
Languages: eng Pagination: 959-65 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, University Hospital Nijmegen, The Netherlands |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Drug Therapy, Combination Fibrinolytic Agents / administration & dosage* Heparin / administration & dosage Humans Myocardial Infarction / drug therapy* Recurrence Thrombolytic Therapy / trends* Time Factors Tissue Plasminogen Activator / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 9005-49-6/Heparin; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nitric oxide and inflammatory bowel disease
Next Document: The surgical treatment of acute myocardial infarct in the 90s